The Daily Brief by ZERODHA serves just not only stock investors on the upcoming businesses but also promotes the noble cause of entrepreneurship development by its Deep Research as it did earlier with Storage Batteries and today by Exploring the starting line for the GLP-1 race.These efforts to make our country better ,is an act of PATRIOTISM ,The semaglutide supply chain issues,likely generic transition,demand as well International existing cos and Indian upcoming cos have been so well covered backed by data,cos preparation etc that it’s a complete dossier of the sector and ecosystem.
I would add access to GLP1 injections drive a parallel boom: the rise of ‘natural substitutes’. Products using naturally-derived ingredients are now being marketed to support GLP1 and GIP hormone pathways. With a polished label, ‘natural’ guarantee, a moneyback promise and five-star reviews, it lures hopeful consumers towards wellness nationwide.Some substitutes, such as BRP, a natural peptide-based alternative to GLP1 drugs, are being researched upon as alternatives with less side-effects. Identified by researchers at Stanford via an AI-driven tool that sifted through thousands of potential hormone fragments, this peptide is taken from the BRINP2 protein through natural processing, and has been detected in biological samples including human cerebrospinal fluid.
The other topic whether
Is Indian industry hidden behind a statistical quirk is. Utmost importance to entire ecosystem including Govt.There are massive caveats. And if they’re true, they seriously weaken the paper’s claim that manufacturing makes 32% of our economy.
The Daily Brief by ZERODHA serves just not only stock investors on the upcoming businesses but also promotes the noble cause of entrepreneurship development by its Deep Research as it did earlier with Storage Batteries and today by Exploring the starting line for the GLP-1 race.These efforts to make our country better ,is an act of PATRIOTISM ,The semaglutide supply chain issues,likely generic transition,demand as well International existing cos and Indian upcoming cos have been so well covered backed by data,cos preparation etc that it’s a complete dossier of the sector and ecosystem.
I would add access to GLP1 injections drive a parallel boom: the rise of ‘natural substitutes’. Products using naturally-derived ingredients are now being marketed to support GLP1 and GIP hormone pathways. With a polished label, ‘natural’ guarantee, a moneyback promise and five-star reviews, it lures hopeful consumers towards wellness nationwide.Some substitutes, such as BRP, a natural peptide-based alternative to GLP1 drugs, are being researched upon as alternatives with less side-effects. Identified by researchers at Stanford via an AI-driven tool that sifted through thousands of potential hormone fragments, this peptide is taken from the BRINP2 protein through natural processing, and has been detected in biological samples including human cerebrospinal fluid.
The other topic whether
Is Indian industry hidden behind a statistical quirk is. Utmost importance to entire ecosystem including Govt.There are massive caveats. And if they’re true, they seriously weaken the paper’s claim that manufacturing makes 32% of our economy.